•  chemotherapy in high risk lobular/mucinous BC?
• Neoadjuvant therapy in premenopausal patients with lobular BC?
  Adjuvant therapy with node negative and node positive lobular BC?
  Adjuvant therapy in luminal BC with RS 16-25?
  Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours??
• Oncotype DX and selection of neoadjuvant  hormonal vs chemotherapy  therapy
• Role of interval Ki67 assessment with neoadjuvant  hormonal therapy

Moderator: Ahmed Alshehri

Panel: